Novartis NVS and AbbVie ABBV announced small M&A deals. The FDA approved the expanded use of Pfizer’s PFE cancer drug ...

We recently compiled a list of the 13 Best Foreign Dividend Stocks To Buy According to Analysts. In this article, we are ...

Novartis' strong drug pipeline and financials support an 11% annual return by 2027. Learn why NVS stock offers 33% return ...

Alnylam Pharmaceuticals exceeded Wall Street's expectations with strong revenue growth and significant commercial progress.

Under the terms of the agreement, Novartis will pay $925 million upfront and up to $2.15 billion, contingent upon achievement ...

Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its ...

Investing.com -- 瑞士制药公司诺华周二宣布，已达成协议收购生物制药公司Anthos Therapeutics。 根据公司声明，此次收购将包括诺华支付9.25亿美元的首付款，以及最高可达21.5亿美元的额外付款。

瑞士制药巨头 诺华 （Novartis）周二表示，已同意以至多30.8亿美元的价格收购美国私人控股的临床阶段生物制药公司Anthos Therapeutics，以扩大其心血管药物管线。

Novartis said it has agreed to acquire U.S. privately held, clinical-stage biopharmaceutical company Anthos Therapeutics for up to $3.08 billion to boost its cardiovascular pipeline.

Dow Jones Newswires is a market-moving financial and business news source, used by wealth managers, institutional investors and fintech platforms around the world to identify trading and investing ...